Search - tctmd.com

Displaying 641 - 660 of 2055

Sort: Relevancy | Date

Presentation TCT 2022

Have We Gotten to the Final Word on Paclitaxel Safety?

Presenter: Eric Secemsky

September 17, 2022

Presentation TCT 2022

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Presenter: Marc Bonaca

September 17, 2022

News Conference News TCT 2022

Primordial Prevention Before End-stage CVD: Experts Call for a Fresh Focus

Yael L. Maxwell

September 16, 2022

News Daily News

Obesity May Boost Thrombotic Events in Contraceptive Users, Review Suggests

L.A. McKeown

September 16, 2022

News Daily News

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Michael O'Riordan

September 15, 2022

News Daily News

Checking Cumulative High BP Exposure Hones CV Risk Prediction in Diabetes

Todd Neale

September 14, 2022

News Daily News

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Michael O'Riordan

September 09, 2022

News Daily News

Older Adults See Rebound in Rates of HF-Related Death: CDC Data

Caitlin E. Cox

September 09, 2022

News Daily News

VITAL Rhythm Data May Flip the Script on AF Screening in Women

L.A. McKeown

September 08, 2022

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Shelley Wood

September 07, 2022

News Conference News ESC 2022

GRACE 3.0: Women With NSTE ACS Get a Boost From Updated Score

Caitlin E. Cox

September 06, 2022

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

Todd Neale

September 01, 2022

News Daily News

New on the Scene Nonstatin Drugs: Experts Provide Guidance

Caitlin E. Cox

August 31, 2022

News Conference News ESC 2022

Large RCTs of High-Dose Flu Vaccines Doable, DANFLU-1 Confirms

Yael L. Maxwell

August 31, 2022

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

News Conference News ESC 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

Michael O'Riordan

August 29, 2022

Presentation ESC 2022

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results of the FOURIER-OLE (Open-Label Extension) Studies

Presenter: Michelle L. O’Donoghue

August 29, 2022

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

News Conference News ESC 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

Todd Neale

August 28, 2022

Advertisement

Have We Gotten to the Final Word on Paclitaxel Safety?

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Primordial Prevention Before End-stage CVD: Experts Call for a Fresh Focus

Obesity May Boost Thrombotic Events in Contraceptive Users, Review Suggests

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Checking Cumulative High BP Exposure Hones CV Risk Prediction in Diabetes

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Older Adults See Rebound in Rates of HF-Related Death: CDC Data

VITAL Rhythm Data May Flip the Script on AF Screening in Women

CV Care Around Noncardiac Surgery: New ESC Guidelines

New Faces, New Formats, New Tech: What to Expect From TCT 2022

GRACE 3.0: Women With NSTE ACS Get a Boost From Updated Score

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

New on the Scene Nonstatin Drugs: Experts Provide Guidance

Large RCTs of High-Dose Flu Vaccines Doable, DANFLU-1 Confirms

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results of the FOURIER-OLE (Open-Label Extension) Studies

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content